Physician profile
Jennifer Devore
NPI 1720328750
$1,710.57
in general payments reported to CMS, 2019-2025
19 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $283 · 2023: $498 · 2024: $346 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.36 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $246.14 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $171.32 | 2025 | Repatha, Krystexxa |
| Mayne Pharma Commercial LLC | $152.71 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.12 | 2022-2025 | |
| Biogen, INC. | $131.75 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $97.36 | 2023-2025 | Myosure Tissue Removal Device, Acessa Provu System, Fetal Fibronectin Enzyme Immunoassay |
| Sumitomo Pharma America, INC. | $95.29 | 2023-2025 | Myfembree |
| Abbvie INC. | $95.10 | 2022-2024 | |
| Pfizer INC. | $78.30 | 2022-2025 | |
| Insulet Corporation | $78.26 | 2023-2025 | Omnipod, Omnipod |
| Vertex Pharmaceuticals Incorporated | $74.33 | 2025 | |
| Exeltis, USA INC. | $74.12 | 2022-2024 | Slynd |
| Organon LLC | $51.81 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $41.02 | 2022-2023 | Gardasil 9 |
| Novo Nordisk INC | $40.12 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $38.17 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Becton, Dickinson and Company | $35.62 | 2024 | Bd Max System, Bd Max Instrument |
| Neurocrine Biosciences, INC. | $32.33 | 2022 | |
| Daiichi Sankyo INC. | $25.70 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.